Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $25.19 Consensus Price Target from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $25.1875.

Several research firms have recently issued reports on ROIV. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. HC Wainwright increased their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 12th. The Goldman Sachs Group boosted their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price target on shares of Roivant Sciences in a research note on Thursday, December 18th. Finally, Leerink Partners increased their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $21.97 on Friday. Roivant Sciences has a fifty-two week low of $8.73 and a fifty-two week high of $23.91. The firm has a market capitalization of $15.28 billion, a P/E ratio of -39.23 and a beta of 1.22. The company’s 50 day simple moving average is $21.95 and its 200 day simple moving average is $17.62.

Insider Buying and Selling

In other Roivant Sciences news, insider Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the transaction, the insider directly owned 20,267,429 shares in the company, valued at approximately $440,005,883.59. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Richard Pulik sold 406,731 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the completion of the transaction, the chief financial officer directly owned 239,413 shares of the company’s stock, valued at approximately $5,370,033.59. The trade was a 62.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 12,332,392 shares of company stock valued at $266,393,645. 10.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds have recently modified their holdings of ROIV. Goldman Sachs Group Inc. grew its position in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after buying an additional 34,341 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Roivant Sciences by 22.9% in the second quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock valued at $90,000 after buying an additional 1,485 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Roivant Sciences by 10.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,261 shares of the company’s stock worth $296,000 after acquiring an additional 2,385 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in shares of Roivant Sciences during the second quarter worth $1,145,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.